X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Cyclica's two highly differentiated products in the digital chemistry space which will be integrated into the Recursion OS, including MatchMaker™, an AI-enabled deep learning engine that predicts the polypharmacology of small molecules and POEM™.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Recursion Pharma
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 08, 2023
Details:
Cyclica’s platform and capabilities in combination with the biological assay development of Arctoris will enable us to yield meaningful results and advance research development for patients suffering from Alzheimers and other neurodegenerative diseases.
Lead Product(s): Cyclosporine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Arctoris
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 23, 2022
Details:
As part of the initiative, the SGC and Cyclica examined three WDR proteins to discover small molecule binders using Cyclica’s proprietary deep learning platform to assess commercially available libraries for potential binders.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Structural Genomics Consortium
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 11, 2021
Details:
Cerevel will utilize Cyclica’s Ligand Express® and Ligand Design™ platforms to screen, identify, evaluate and optimize targets to develop neuroscience medicines.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cerevel Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 27, 2020
Details:
Under the initial stealth project, NeuroTheryX combined their phenotype-based drug discovery platform with Cyclica’s first-in-class proteome screening platform.
Lead Product(s): Cannabinoid-based product
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: NineteenGale Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
